Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lonza is a Swiss contract development and manufacturing organization (CDMO) serving pharmaceutical and biotech clients with biologics manufacturing, cell and gene therapy production, and small molecule APIs. The company operates 40+ manufacturing sites globally with particular strength in mammalian cell culture for monoclonal antibodies and viral vector production for gene therapies. Lonza's competitive position rests on technical expertise in complex biologics, long-term supply agreements with major pharma, and significant capital investments in specialized manufacturing capacity.
Lonza generates revenue through multi-year manufacturing contracts with pharmaceutical and biotech companies, charging for development services, technology transfer, clinical-scale production, and commercial-scale manufacturing. Pricing power derives from high switching costs (regulatory approval tied to specific manufacturing sites), technical complexity of biologics production, and capacity constraints industry-wide. The company benefits from take-or-pay contract structures that guarantee minimum volumes, providing revenue visibility. Margins expand as facilities scale from clinical to commercial production, with commercial manufacturing generating 40-50% gross margins versus 25-35% for development work.
New contract wins and capacity bookings - particularly large-scale biologics agreements or cell/gene therapy partnerships that signal multi-year revenue streams
Utilization rates at key biologics facilities - especially Visp (Switzerland), Portsmouth (US), and Singapore sites where capacity tightness drives pricing power
Cell and gene therapy pipeline progress - clinical trial advancement of client programs using Lonza's viral vector or cell therapy manufacturing drives future commercial revenue expectations
Pharma R&D spending trends and biotech funding environment - impacts demand for CDMO services as clients outsource manufacturing to preserve capital
Technology shift risk as new modalities (mRNA, cell therapies, gene editing) require different manufacturing infrastructure - Lonza's $1.4B annual capex addresses this but creates execution risk if platform investments don't achieve commercial scale
Regulatory concentration risk with manufacturing sites requiring FDA, EMA, and other agency approvals - any compliance issues or warning letters can shut down facilities and breach client contracts, as seen periodically across the CDMO industry
Biosimilar competition reducing margins on legacy biologics manufacturing as patents expire on blockbuster antibodies, shifting mix toward lower-margin products
Capacity expansion by competitors (Catalent, Samsung Biologics, WuXi Biologics) potentially creating oversupply in biologics manufacturing by 2027-2028, pressuring utilization and pricing
Vertical integration by large pharma bringing manufacturing in-house for strategic products, reducing outsourcing demand - though capital intensity and regulatory complexity limit this trend
Chinese CDMO competitors offering 30-40% cost advantages, particularly for small molecules and early-stage development work, though geopolitical concerns and quality perceptions favor Western manufacturers
Negative free cash flow of $200M despite $1.2B operating cash flow reflects aggressive capex spending at 21% of revenue - execution delays or demand shortfalls could impair returns on these investments
Currency exposure as Swiss franc-denominated cost base faces euro and dollar revenue streams - CHF strength compressed margins historically, though hedging programs mitigate near-term volatility
low - Pharmaceutical manufacturing demand is largely non-cyclical as drug production continues regardless of economic conditions. However, biotech funding cycles create moderate sensitivity, as venture capital availability affects small biotech clients' ability to fund clinical programs and outsourced manufacturing. The 18-36 month lag between contract signing and revenue recognition dampens immediate economic impacts. Lonza's revenue mix toward commercial manufacturing (versus development) provides stability.
Rising interest rates create moderate headwinds through two channels: (1) biotech client funding becomes more expensive, potentially delaying clinical programs and CDMO contract awards, particularly for early-stage companies; (2) Lonza's valuation multiple compresses as investors discount future cash flows at higher rates, though the company's 0.46 debt/equity ratio limits direct financing cost impacts. The negative FCF reflects heavy capex investment, making the cost of capital relevant for project returns.
Moderate exposure through biotech client creditworthiness. While large pharma clients (estimated 60-70% of revenue) have minimal default risk, smaller biotech clients may face funding challenges in tight credit environments, potentially leading to contract delays or cancellations. Lonza typically requires upfront payments and milestone-based billing to mitigate this risk. The company's own credit profile is strong with investment-grade ratings, limiting direct credit market dependence.
growth-at-reasonable-price (GARP) - Lonza attracts investors seeking exposure to structural growth in biologics and advanced therapies with more reasonable valuations than pure biotech. The 5.7x price/sales and 22.5x EV/EBITDA multiples reflect premium positioning but not extreme growth expectations. The 51.7% EPS growth (likely reflecting margin recovery) appeals to growth investors, while 10.2% ROE and negative FCF deter pure value investors. Institutional healthcare specialists dominate ownership given the technical complexity and long investment horizons required.
moderate - As a large-cap healthcare services company with diversified client base and long-term contracts, Lonza exhibits lower volatility than biotech but higher than diversified pharma. Beta likely in 0.8-1.1 range. Stock moves on quarterly earnings surprises, major contract announcements, and shifts in biotech funding sentiment. The 10.6% one-year return versus 5.5% three-month return suggests recent momentum, while 0% six-month return indicates consolidation periods between catalysts.
